Norbert Grząśko

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice

Artur Jurczyszyn, Norbert Grząśko, Alessandro Gozzetti et al. · American Journal of Hematology · 2016 · 141 citations · Full text

Medicine, Hematology, Oncology +14

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, Shaji Kumar, Tamás Masszi et al. · Journal of Clinical Oncology · 2021 · 99 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · Blood · 2015 · 69 citations

Medicine, Oncology, Pharmacology +15

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

Dominik Dytfeld, Magdalena Łuczak, Tomasz Wróbel et al. · Oncotarget · 2016 · 68 citations · Full text

Medicine, Molecular Medicine, Oncology +17